Evidence map›Paper›PMID 23121771›Full record

ArticleClinical and translational allergy2012

Research needs in allergy: an EAACI position paper, in collaboration with EFA.

Nikolaos G Papadopoulos, Ioana Agache, Sevim Bavbek, Beatrice M Bilo, Fulvio Braido, Victoria Cardona, Adnan Custovic, Jan Demonchy, Pascal Demoly, Philippe Eigenmann and 126 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational allergy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 207 citations in OpenAlex.

  1. Article
  2. Article
  3. Birch rust allergy as a novel autumnal trigger of seasonal airway symptoms.The journal of allergy and clinical immunology. Global · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Asthma and stem cell therapy.World journal of stem cells · 2025
    Review
  11. Article
  12. Bacteria and Allergic Diseases.International journal of molecular sciences · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

136 authors at 20 institutions in 25 countries.

Nikolaos G PapadopoulosAllergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece. ngp@allergy.gr.
Ioana Agache
Sevim Bavbek
Beatrice M Bilo
Fulvio Braido
Victoria Cardona
Adnan Custovic
Jan Demonchy
Pascal Demoly
Philippe Eigenmann
Jacques Gayraud
Clive Grattan
Enrico Heffler
Peter W Hellings
Marek Jutel
Edward Knol
Jan Lötvall
Antonella Muraro
Lars K Poulsen
Graham Roberts
Peter Schmid-Grendelmeier
Chrysanthi Skevaki
Massimo Triggiani
Ronald Vanree
Thomas Werfel
Breda Flood
Susanna Palkonen
Roberta Savli
Pia Allegri
Isabella Annesi-Maesano
Francesco Annunziato
Dario Antolin-Amerigo
Christian Apfelbacher
Miguel Blanca
Ewa Bogacka
Patrizia Bonadonna
Matteo Bonini
Onur Boyman
Knut Brockow
Peter Burney
Jeroen Buters
Indre Butiene
Moises Calderon
Lars Olaf Cardell
Jean-Christoph Caubet
Sevcan Celenk
Ewa Cichocka-Jarosz
Cemal Cingi
Mariana Couto
Nicolette Dejong
Stefano Del Giacco
Nikolaos Douladiris
Filippo Fassio
Jean-Luc Fauquert
Javier Fernandez
Montserrat Fernandez Rivas
Marta Ferrer
Carsten Flohr
James Gardner
Jon Genuneit
Philippe Gevaert
Anna Groblewska
Eckard Hamelmann
Hans Jürgen Hoffmann
Karin Hoffmann-Sommergruber
Lilit Hovhannisyan
Valérie Hox
Frode L Jahnsen
Omer Kalayci
Ayse Füsun Kalpaklioglu
Jörg Kleine-Tebbe
George Konstantinou
Marcin Kurowski
Susanne Lau
Roger Lauener
Antti Lauerma
Kirsty Logan
Antoine Magnan
Joanna Makowska
Heidi Makrinioti
Paraskevi Mangina
Felicia Manole
Adriano Mari
Angel Mazon
Clare Mills
Ervinç Mingomataj
Bodo Niggemann
Gunnar Nilsson
Markus Ollert
Liam O'Mahony
Serena O'Neil
Gianni Pala
Alberto Papi
Gianni Passalacqua
Michael Perkin
Oliver Pfaar
Constantinos Pitsios
Santiago Quirce
Ulrike Raap
Monika Raulf-Heimsoth
Claudio Rhyner
Paula Robson-Ansley
Rodrigo Rodrigues Alves
Zeljka Roje
Carmen Rondon
Odilija Rudzeviciene
Franziska Ruëff
Maia Rukhadze
Gabriele Rumi
Cansin Sackesen
Alexandra F Santos
Annalisa Santucci
Christian Scharf
Carsten Schmidt-Weber
Benno Schnyder
Jürgen Schwarze
Gianenrico Senna
Svetlana Sergejeva
Sven Seys
Andrea Siracusa
Isabel Skypala
Milena Sokolowska
Francois Spertini
Radoslaw Spiewak
Aline Sprikkelman
Gunter Sturm
Ines Swoboda
Ingrid Terreehorst
Elina Toskala
Claudia Traidl-Hoffmann
Carina Venter
Berber Vlieg-Boerstra
Paul Whitacker
Margitta Worm
Paraskevi Xepapadaki
Cezmi A Akdis
National and Kapodistrian University of Athens · GRAcademic Medical Center · NLEuropean Federation of Allergy and Airways Diseases Patients Associations · BETechnical University of Munich · DECharité - Universitätsmedizin Berlin · DECK-CARE · CHImperial College London · GBInstitut du Thorax · FRJagiellonian University · PLMedical University of Vienna · ATMedizinische Hochschule Hannover · DERoyal Brompton Hospital · GBUniversity of Ferrara · ITUniversity of Manchester · GBUniversity of Zurich · CHVilnius University · LTWroclaw Medical University · PL424 General Military Hospital · GRAarhus University Hospital · DKAIDS and Clinical Immunology Research Center · GE

Funding

Department of Health PDF/01/055Medical Research Council G0902018Medical Research Council G1002033
6 · The paper itself

Abstract

In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems. More disturbingly, its prevalence and impact are on the rise, a development that has been associated with environmental and lifestyle changes accompanying the continuous process of urbanization and globalization. Therefore, there is an urgent need to prioritize and concert research efforts in the field of allergy, in order to achieve sustainable results on prevention, diagnosis and treatment of this most prevalent chronic disease of the 21st century.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading professional organization in the field of allergy, promoting excellence in clinical care, education, training and basic and translational research, all with the ultimate goal of improving the health of allergic patients. The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is a non-profit network of allergy, asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients' organizations. In support of their missions, the present EAACI Position Paper, in collaboration with EFA, highlights the most important research needs in the field of allergy to serve as key recommendations for future research funding at the national and European levels.Although allergies may involve almost every organ of the body and an array of diverse external factors act as triggers, there are several common themes that need to be prioritized in research efforts. As in many other chronic diseases, effective prevention, curative treatment and accurate, rapid diagnosis represent major unmet needs. Detailed phenotyping/endotyping stands out as widely required in order to arrange or re-categorize clinical syndromes into more coherent, uniform and treatment-responsive groups. Research efforts to unveil the basic pathophysiologic pathways and mechanisms, thus leading to the comprehension and resolution of the pathophysiologic complexity of allergies will allow for the design of novel patient-oriented diagnostic and treatment protocols. Several allergic diseases require well-controlled epidemiological description and surveillance, using disease registries, pharmacoeconomic evaluation, as well as large biobanks. Additionally, there is a need for extensive studies to bring promising new biotechnological innovations, such as biological agents, vaccines of modified allergen molecules and engineered components for allergy diagnosis, closer to clinical practice. Finally, particular attention should be paid to the difficult-to-manage, precarious and costly severe disease forms and/or exacerbations. Nonetheless, currently arising treatments, mainly in the fields of immunotherapy and biologicals, hold great promise for targeted and causal management of allergic conditions. Active involvement of all stakeholders, including Patient Organizations and policy makers are necessary to achieve the aims emphasized herein.

Identifiers

PMID23121771
PMCPMC3539924
OpenAlexW2172112917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.